Navigation Links
TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F-expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved specific therapies for PV, ET and PMF. These disorders are estimated to affect approximately 200,000 patients in the United States and more than twice that total worldwide.

The current clinical trial is being conducted at multiple centers in the USA. The trial is expected to enroll between 40-80 patients. Primary goals of this open label dose escalating protocol include identification of a maximum tolerated dose (MTD), accumulation of safety data, measurement of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 7, 2017  Eli Lilly and Company (NYSE: ... streamline operations to more efficiently focus resources on ... structure. Global workforce reductions, including those from a ... impact approximately 3,500 positions. With ... savings of approximately $500 million that will begin ...
Breaking Medicine Technology:
(Date:9/24/2017)... ... September 25, 2017 , ... The Venetian on Grace ... on October 1st. And, throughout the month of October, the resort will be ... Hurricane Irma and Maria have passed and damage to the Venetian was very minimal ...
(Date:9/24/2017)... ... ... “The Messiah 8 with the 3rd Anti Christ”: a forceful and dynamic narrative ... 3rd Anti Christ” is the creation of published author, Albert Velazquez. , ... life,” Velazquez states, “I always come to the same conclusion: God loves working in ...
(Date:9/23/2017)... ... 23, 2017 , ... A September 5 article ... director of Chicago’s Center for Lifestyle Medicine at Northwestern Medicine. While explaining Dr. ... that the center routinely recommends weight loss surgeries for patients who meet the ...
(Date:9/22/2017)... ... September 22, 2017 , ... On Sunday, September 24, hundreds will gather ... Florence Joyner, still considered the fastest woman of all time. Flo Jo passed ... Joyner, will sing the National Anthem. Mary was a contestant on the 2012 ...
(Date:9/22/2017)... ... September 22, 2017 , ... After a long health ... a new lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief ... with unsecured debt. The senior is one of the satisfied clients who expressed ...
Breaking Medicine News(10 mins):